Abstract: In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).

Abstract: In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).

Abstract: In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).

Abstract: In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).

Abstract: A delivery apparatus according to the present application includes an acquisition unit, a generation unit, and a delivery unit. The acquisition unit acquires user information that represents information relating to a user. The generation unit generates, using the user information acquired by the acquisition unit, loan information that represents information including loan terms for the user. The delivery unit delivers the loan information generated by the generation unit to a terminal apparatus that is used by the user by using, as a trigger, display of predetermined service content at the terminal apparatus.

Abstract: In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).

Abstract: In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).

Abstract: The present invention provides an optical isomer separating agent and a production method thereof. That is, the present invention provides a one-handed helical poly(diphenylacetylene) compound represented by the following formula (I) [wherein each symbol is as described in the DESCRIPTION], and a production method thereof, an optical isomer separating agent containing the poly(diphenylacetylene) compound, and a packing material for a chiral column, containing the optical isomer separating agent coated on a carrier. Since these have a superior separation ability for a wide variety of compounds, a practical optical resolution method can be provided.

Abstract: The present invention provides an optical isomer separating agent and a production method thereof. That is, the present invention provides a one-handed helical poly(diphenylacetylene) compound represented by the following formula (I) [wherein each symbol is as described in the DESCRIPTION], and a production method thereof, an optical isomer separating agent containing the poly(diphenylacetylene) compound, and a packing material for a chiral column, containing the optical isomer separating agent coated on a carrier. Since these have a superior separation ability for a wide variety of compounds, a practical optical resolution method can be provided.

Abstract: In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).

Abstract: Provided is a control method for a computer system including one or more host computers, one or more storage systems, and a management computer. The storage system includes a plurality of controllers connected to the host computers through a network, and one or more logical volumes for storing data used by the host computers. At least one of the logical volumes is assigned to at least one of the controllers. According to the control method, when performance information of a controller exceeds a predetermined threshold, the logical volume assigned to the controller is assigned to another controller other than the controller. Thus, access loads on a storage system used in a network environment are balanced.

Abstract: Provided is a computer system including at least one host computer; and at least one storage system, characterized in that: the storage system has a disk drive and a disk controller, and provides a storage area of the disk drive as at least one logical unit; upon detecting a failure in a logical path serving as an access route from the host computer to the logical unit, the host computer specifies logical paths for accessing the same logical unit that is connected to the logical path where the failure is detected; the host computer executes failure detecting processing for the specified logical paths to judge whether the specified logical paths are normal or not; the host computer selects normal logical paths out of the specified logical paths; and the host computer accesses the logical unit via the normal logical paths selected.

Abstract: In the computer system including a host computer and a storage system, the storage system includes a physical disk and a disk controller, and provides a storage area of the physical disk as at least one logical unit. The processor obtains, at a first time point and a second time point different from the first time point, a relation between a logical path and a component through which the logical path passes, stores, as logical path connection information, the relations obtained at the first time point and the second time point, refers to the logical path connection information to compare the logical paths existing at the first time point and the logical paths existing at the second time point with each other, and specifies the logical path which does not exist at the second time point among the logical paths existing at the first time point.

Abstract: In the computer system including a host computer and a storage system, the storage system includes a physical disk and a disk controller, and provides a storage area of the physical disk as at least one logical unit. The processor obtains, at a first time point and a second time point different from the first time point, a relation between a logical path and a component through which the logical path passes, stores, as logical path connection information, the relations obtained at the first time point and the second time point, refers to the logical path connection information to compare the logical paths existing at the first time point and the logical paths existing at the second time point with each other, and specifies the logical path which does not exist at the second time point among the logical paths existing at the first time point.

Abstract: Crystals of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one having a diffraction peak at a diffraction angle (2?±0.2°) of 9.7° and/or 21.9° in a powder X-ray diffraction are suitable for an active ingredient of a preventing and therapeutic agent for diseases such as constipation. Crystals of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one hydrate and amorphous 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one hydrate are also suitable for an active ingredient of a preventing and therapeutic agent for diseases such as constipation.

Abstract: Provided is a computer system including at least one host computer; and at least one storage system, characterized in that: the storage system has a disk drive and a disk controller, and provides a storage area of the disk drive as at least one logical unit; upon detecting a failure in a logical path serving as an access route from the host computer to the logical unit, the host computer specifies logical paths for accessing the same logical unit that is connected to the logical path where the failure is detected; the host computer executes failure detecting processing for the specified logical paths to judge whether the specified logical paths are normal or not; the host computer selects normal logical paths out of the specified logical paths; and the host computer accesses the logical unit via the normal logical paths selected.

Abstract: Provided is a computer system including at least one host computer; and at least one storage system, characterized in that: the storage system has a disk drive and a disk controller, and provides a storage area of the disk drive as at least one logical unit; upon detecting a failure in a logical path serving as an access route from the host computer to the logical unit, the host computer specifies logical paths for accessing the same logical unit that is connected to the logical path where the failure is detected; the host computer executes failure detecting processing for the specified logical paths to judge whether the specified logical paths are normal or not; the host computer selects normal logical paths out of the specified logical paths; and the host computer accesses the logical unit via the normal logical paths selected.

Abstract: In the computer system including a host computer and a storage system, the storage system includes a physical disk and a disk controller, and provides a storage area of the physical disk as at least one logical unit. The processor obtains, at a first time point and a second time point different from the first time point, a relation between a logical path and a component through which the logical path passes, stores, as logical path connection information, the relations obtained at the first time point and the second time point, refers to the logical path connection information to compare the logical paths existing at the first time point and the logical paths existing at the second time point with each other, and specifies the logical path which does not exist at the second time point among the logical paths existing at the first time point.

Abstract: Crystals of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one having a diffraction peak at a diffraction angle (2?±0.2°) of 9.7° and/or 21.9° in a powder X-ray diffraction are suitable for an active ingredient of a preventing and therapeutic agent for diseases such as constipation. Crystals of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one hydrate and amorphous 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one hydrate are also suitable for an active ingredient of a preventing and therapeutic agent for diseases such as constipation.

Abstract: Crystals of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one having a diffraction peak at a diffraction angle (2?±0.2°) of 9.7° and/or 21.9° in a powder X-ray diffraction are suitable for an active ingredient of a preventing and therapeutic agent for diseases such as constipation. Crystals of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one hydrate and amorphous 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one hydrate are also suitable for an active ingredient of a preventing and therapeutic agent for diseases such as constipation.